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Activation of the extracellular signal-regulated kinase (ERK) 1/2 cascade by polypeptide growth factors is
tightly coupled to adhesion to extracellular matrix in nontransformed cells. Raf-1, the initial kinase in this
cascade, is intricately regulated by phosphorylation, localization, and molecular interactions. We investigated
the complex interactions between Raf-1, protein kinase A (PKA), and p21-activated kinase (PAK) to determine
their roles in the adhesion dependence of signaling from epidermal growth factor (EGF) to ERK. We conclude
that Raf-1 phosphorylation on serine 338 (S338) is a critical step that is inhibited in suspended cells.
Restoration of phosphorylation at S338, either by expression of highly active PAK or by expression of an S338
phospho-mimetic Raf-1 mutation, led to a partial rescue of ERK activation in suspended cells. Raf-1 inhibition
in suspension was not due to excessive negative regulation on inhibitory sites S43 and S259, as these serines
were largely dephosphorylated in suspended cells. Finally, strong phosphorylation of Raf-1 S338 provided
resistance to PKA-mediated inhibition of ERK activation. Phosphorylation at Raf-1 S43 and S259 by PKA only
weakly inhibited EGF activation of Raf-1 and ERK when cells maintained high Raf-1 S338 phosphorylation.
Cell adhesion through integrins to extracellular matrix
(ECM) and stimulation by soluble mitogens cooperate in co-
ordinating numerous cellular events, including migration, sur-
vival, and proliferation. Integrin engagement results in the
recruitment of structural proteins, including talin, vinculin, and
paxillin, to focal complexes, specialized adhesive structures
that can signal through activation of kinases, such as FAK and
Src (1). Entry into the cell cycle normally requires both adhe-
sion to an appropriate ECM, with concurrent organization of
the cytoskeleton, and stimulation by growth factors (6). In
adherent cells, polypeptide growth factors, such as epidermal
growth factor (EGF), activate receptor tyrosine kinases that
lead to GTP loading of Ras and activation of the Raf-1/MEK/
ERK kinase cascade. Activated extracellular signal-regulated
kinase (ERK) can translocate to the nucleus, phosphorylate
transcription factors, and induce growth-regulatory genes such
as cyclin D1 (29). Loss of adhesion or breakdown of the cy-
toskeleton disrupts focal complexes and blocks ERK activation
(2) and cell proliferation in nontransformed cells (58). Con-
versely, the uncoupling of growth factor signaling from cell
anchorage is a hallmark of malignant transformation (37).
Loss of integrin engagement can influence ERK activation
at several points within the signaling cascade. Growth factor
receptors have been shown to associate in complexes with
integrins in an extracellular matrix-dependent fashion (47),
which may concentrate receptors at sites on the plasma mem-
brane to enhance receptor activation (42). Cell detachment
from the substratum leads to activation of phosphatases (38)
that inhibit ERK activation directly. The organization of the
cytoskeleton can also influence kinases, such as protein kinase
C (PKC), Src, or p21-activated kinase (PAK) (34), which fa-
cilitate Raf-1 or MEK activation. Finally, even with forced
activation of ERK in suspended cells, loss of cytoskeletal in-
tegrity inhibits ERK translocation to the nucleus (3).
In NIH 3T3 fibroblasts, Ras becomes equally GTP loaded in
adherent or suspended cells treated with growth factors, indi-
cating that the signaling pathway is intact to this point (41, 45).
We have found that activation of Raf-1 is a key adhesion-
dependent step downstream of Ras (41), although others have
suggested that abrogation of growth factor signaling in nonad-
herent cells primarily involves MEK (45). Raf-1 is regulated by
functional interactions with many proteins, including kinases
(Src, PAK, PKA, PKC, and Akt), phosphatases (PP1 and
PP2A), and scaffolding proteins (14-3-3, Hsp90, KSR, and
RKIP) (22). Unlike many kinases in which simple phosphory-
lation of a catalytic loop leads to activation, Raf-1 contains
many phospho-regulatory sites, including serines (43, 233, 259,
338, 339, 491, and 621), threonine (494), and tyrosines (340
and 341). The PAKs (10, 49, 51) as well as a rho-dependent
kinase (39) seem to play an important role in anchorage-de-
pendent regulation in the ERK cascade. PAK3 phosphorylates
Raf-1 on serine 338 (S338), a step that is required for efficient
Raf-1 and ERK activation (10). Mutation of Raf-1 S338 to
alanine results in a nonactivatable kinase (10, 13). Phosphory-
lations at this site are not activating for Raf-1 but are thought
to relieve an autoinhibitory state to permit activation (17, 51).
Importantly, the PAK family kinases are poorly activated in
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suspended cells due to lack of interaction between PAK and
GTP-loaded Rac or cdc42 (19, 20) and because of inhibition by
PKA (34).
PKA is a promiscuous kinase also involved in adhesion-
dependent signaling to ERK. PKA is transiently activated
upon detachment from the substratum (34) and can phosphor-
ylate and inhibit both PAK (34) and Raf-1 (25, 30). PKA
activation can have many effects throughout the cell that may
impinge on Raf-1 signaling, including cytoskeletal disruption
and phosphatase activation. PKA can also directly phosphor-
ylate Raf-1 on at least two critical sites. Phosphorylation of
Raf-1 S43 inhibits the Ras–Raf-1 interaction, which is crucial
for Raf-1 translocation and activation (4). Phosphorylation of
Raf-1 S233 or S259 is thought to inhibit Raf-1 by enhancing
14-3-3 binding to these sites and restricting Raf-1 intra- or
intermolecular interactions (26).
The goal of this study was to investigate how cells translate
physical adhesion to ECM into critical biochemical events that
allow for efficient signaling within the cell. We examined the
complex interactions between Raf-1, PKA, and PAK to deter-
mine their roles in the adhesion dependence of signaling from
EGF to ERK in NIH 3T3 fibroblasts and HEK293 cells. We
conclude that the adhesion-dependent regulation of ERK in
EGF-treated cells occurs at the level of Raf-1. Unlike adherent
cells, suspended cells do not phosphorylate Raf-1 S338 effi-
ciently upon EGF treatment. Raf-1 from suspended cells is
generally dephosphorylated on S43 and S259, and so it seems
that it is loss of the permissive S338 phosphorylation, rather
than excessive inhibitory phosphorylation, that is critical. Res-
toration of phosphorylation at S338, either by expression of a
highly active version of PAK1 (PAK165) or by expression of a
phospho-mimetic mutation (Raf-1 S338D) leads to a partial
rescue of ERK activation in suspended cells.
PKA activation also plays a critical role in suspended cells.
Inhibition of PKA during detachment from the substratum
leads to rescue of Raf-1 S338 phosphorylation and partial ERK
activation. In adherent cells, PKA activation by forskolin in-
duces Raf-1 phosphorylation on S43 and S259 and inhibits
phosphorylation of Raf-1 on S338 and subsequent ERK acti-
vation. However, ERK activation can be observed in cells
treated with forskolin, provided that S338 is forced to be highly
phosphorylated. ERK activation in these cells persists despite
phosphorylation on the inhibitory S43 and S259 sites. These
observations reveal important insights into how cell adhesion
influences positive and negative regulatory phosphorylations in
Raf-1 activation with subsequent consequences for signaling in
the ERK/MAP kinase pathway.
MATERIALS AND METHODS
Materials. Forskolin, H89 (Biomol, Plymouth Meeting, PA), and isobutyl-
methyl-xanthene (IBMX; Sigma, St. Louis, MO) were maintained as stock solu-
tions in dimethyl sulfoxide (DMSO) at 20°C. Antibodies to Flag (M2; Sigma),
hemagglutinin (HA; Covance), ERK (sc-31; Santa Cruz Biotechnology, Santa
Cruz, CA), -14-3-3 (sc-629; Santa Cruz Biotechnology), pERK (Sigma),
pS338Raf-1 (05538; Upstate Biotechnology Inc. [UBI], Lake Placid, NY),
pS259Raf-1 (Cell Signaling, Beverly, MA), Raf-1 (sc-133; Santa Cruz Biotech-
nology), CREB and pCREB-133 (Cell Signaling), pS43 Raf-1 (Biosource, Cam-
arillo, CA), pY340/341 (Sigma), 4G10 (UBI), and B-Raf (UBI) were obtained.
Trypsin 0.25%–0.5 mM EDTA and soybean trypsin inhibitor (Gibco), bovine
serum albumin (Sigma), -estradiol (Sigma), fibronectin (Fn; BD Biosciences,
Bedford, MA), EGF (UBI), myelin basic protein (MBP; UBI), ATP (Cell Sig-
naling), [-32P]ATP (New England Nuclear, Boston, MA), and phosphate-buff-
ered saline (PBS) were also used.
Cell culture. NIH 3T3 cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma) supplemented to 10% newborn calf serum (Sigma) at
37°C and 5% CO2. HEK293 cells were maintained in DMEM supplemented to
10% fetal calf serum (Sigma) at 37°C and 5% CO2.
Adhesion-dependent signaling assay. Cells were transfected using Superfect
(QIAGEN) and were recovered for 12 h. Flag–Raf-1 constructs were transfected
at minimum amounts needed to detect effects on signaling: 30% of total trans-
fected DNA for NIH 3T3 cells and 10% of total transfected DNA for HEK293
cells. Cells were grown to near confluence before serum starvation for 12 h in
serum-free DMEM. Cells were detached with trypsin-EDTA, blocked with 1
mg/ml soybean trypsin inhibitor, centrifuged at 300  g, and resuspended in
DMEM containing 1% bovine serum albumin. Cells were rocked at 37°C for 30
min, replated to wells coated with 10 g/ml Fn, or kept in suspension on a rocker
at 37°C. After 2 h of plating or rocking, cells were treated with 10 ng/ml EGF for
5 min and then quenched with ice-cold PBS. Cells were centrifuged and washed
twice with cold PBS before lysis in modified RIPA buffer (50 mM Tris [pH 7.4],
1% NP-40, 0.5% deoxycholic acid, 2 mM EDTA, 50 mM NaF) supplemented
with 500 kallikrein inhibitor units/ml aprotinin, 0.5 mM AEBSF [4-(2-aminoeth-
yl)benzenesulfonyl fluoride], 1 mM 4-nitrophenyl phosphate, 1 mM sodium van-
adate, 5 mM benzamidine, and 0.2 M calyculin A. Lysates were clarified by
centrifugation at 14,000  g, and the supernatant (whole-cell lysate) was used for
immunoprecipitation or sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) separation.
Kinase assays. HA-tagged ERK and Flag-tagged Raf-1 were immunoprecipi-
tated with antibodies and Fast-Flow G–Sepharose beads (Amersham, Uppsala,
Sweden). HA-ERK activity was assayed with [32P]ATP and MBP as previously
described (20). Flag–Raf-1 activity was assessed using the Raf-1-coupled kinase
reaction kit following the manufacturer’s protocols (UBI). Incorporation of
[32P]ATP into MBP was quantified after SDS-PAGE separation of proteins,
exposure of dried gels to phosphorimager cassettes, and analysis on a Storm 840
PhosphorImager (Becton-Dickinson). Kinase activity was adjusted for kinase
loading based on densitometric analysis of Western blots (Fluor-S MultiImager;
Bio-Rad, Philadelphia, PA). Measurements for adherent cells treated with EGF
were set to 100% signal, and other lanes were recalculated accordingly. Graphs
with error bars represent means and standard errors of multiple assays.
Constructs. Flag-tagged Raf-1 constructs (wild type [wt], S338D, and S338A)
were generously provided by K. L. Guan (13). Flag–Raf-1CAAX and Flag–Raf-
1CAAX338A were obtained from P. Stork (8). PAK165, a highly active N-
terminal truncation of Rat PAK1 consisting of residues 165 to 544 (lacking the
autoinhibitory and CRIB domains) was obtained from Melanie Cobb. The par-
ent vector pCMVm5 was used as a negative control vector. PKI (8-22) is a small
peptide inhibitor of PKA; PKI mut2, a double point mutant of PKI that does not
inhibit PKA activation, was used as a negative vector control (34). Raf-1CAAX
(from Channing Der), GFP–Raf-1:ER (from Julian Downward), and HA-tagged
ERK (from Jacques Pouyssegur) were also used. GFPERK2 (from Kathryn
DeFea) was used as a marker for ERK activation in transfected cells and is
readily distinguishable from ERK1/2 based on size (65 kDa). Raf-1 small inhib-
itory RNA (siRNA) was obtained from Ambion (catalog number 51197; Hunt-
ingdon, United Kingdom). B-Raf siRNA (AGAAUUGGAUCUGGAUCAU)
(33, 53) and our control siRNA (MDR1; GUAUUGACAGCUAUUCGAA)
were produced by Dharmacon (Lafayette, CO).
RESULTS
EGF activation of Raf-1 and ERK are tightly coupled to
adhesion. A standard assay was used to examine the factors
critical for adhesion-dependent ERK activation downstream of
EGF. Both HEK293 cells and NIH 3T3 fibroblasts were serum
starved, detached with trypsin, washed, and placed into sus-
pension for 30 min. Cells were then either maintained in sus-
pension or adhered to plates coated with 10 g/ml fibronectin
for 2 h before a 5-min treatment with 10 ng/ml EGF. Cell
lysates were subsequently analyzed for phosphorylation events
and kinase activity.
Our laboratory (41) and others (28, 45) have shown that Ras
GTP loading in this setting is at least as high in suspended cells
as in adherent cells. Thus, we focused on the downstream
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elements of the ERK signaling cascade. In both HEK293 cells
and NIH 3T3 fibroblasts, cells held in suspension showed little
ERK activation loop phosphorylation in response to EGF
treatment compared to those readhered to fibronectin (Fig.
1A). The lack of ERK phosphorylation in suspension corre-
lated with lack of activation, as quantified by an in vitro ERK
kinase assay using MBP (Fig. 1B). To quantify Raf-1 activa-
tion, we immunoprecipitated Raf-1 from NIH 3T3 fibroblasts
and used a Raf-1-coupled kinase reaction. Figure 1B shows
that Raf-1 activation was impaired in nonadherent cells. Sus-
pension did not appear to inhibit signaling downstream of
Raf-1, as RafCAAX expression in HEK293 cells led to phos-
phorylation of coexpressed GFPERK that was independent of
both EGF and adhesion to Fn (Fig. 1C). Similarly, the Raf-1–
estrogen receptor fusion protein (Raf-1:ER) induced similar
phosphorylation of GFPERK after estradiol treatment in both
adherent and suspended cells (Fig. 1D). These observations
indicate that Raf-1 is a key locus for anchorage regulation of
signaling in this context.
Raf-1 S338 phosphorylation is lost in suspension, but its
restoration rescues signaling to ERK. In adherent NIH 3T3
cells in serum-free medium, Raf-1 phosphorylation on S338
was at a low level but could be stimulated by EGF treatment.
By contrast, EGF failed to cause phosphorylation of Raf-1
S338 in cells in suspension (Fig. 2A).
We could restore Raf-1 S338 phosphorylation in suspended
cells through expression of activated PAK (Fig. 2B). PAK165 is
an N-terminal truncation of PAK1 that lacks the autoinhibitory
and p21 binding domains and is highly active. PAK165 caused
a high level of Raf-1 S338 phosphorylation compared to EGF
stimulation, and this was not affected by placing cells in sus-
pension. Phosphorylation of S338 was not activating for Raf-1
by itself but led to a partial rescue of EGF-stimulated ERK
signaling in suspended cells (Fig. 2C).
The amount of Raf-1 S338 phosphorylation in adherent,
EGF-treated NIH 3T3 cells was quite low compared to that
which was maximally possible (as in PAK165-treated cells)
(Fig. 2B). Thus, it appears that only a small fraction of Raf-1
needs to become S338 phosphorylated and activated in adher-
ent cells in order to permit efficient signaling to ERK. By
contrast, in order to partially rescue signaling to ERK in sus-
FIG. 1. Adhesion dependence of ERK activation by EGF is regu-
lated at the level of Raf-1. (A) ERK phosphorylation by Western
blotting. NIH 3T3 fibroblasts or HEK293 cells were serum starved and
plated to fibronectin-coated plates (Fn) or rocked in suspension
(Fn) for 2 h before treatment with () or without () 10 ng/ml EGF
for 5 min. Whole-cell lysates were resolved by SDS-PAGE and were
probed (Western blotted) with antibodies to pERK and ERK.
(B) ERK and Raf kinase assays. HA-ERK and Flag–Raf-1 activation
was determined from EGF-treated NIH 3T3 cells under adherent and
suspended conditions. Immunoprecipitates were quantified for activity
using radioactive kinase assays (see Materials and Methods). Adher-
ent, EGF-treated cell activity was set to 100, and other conditions were
normalized. Means and standard deviations of three independent ex-
periments are shown. (C and D) Effects of constitutively activated Raf
on signaling to ERK. (C) HEK293 cells were cotransfected with
GFPERK and Raf-1 wt (500 ng) or Raf-1CAAX (10 ng) and analyzed
for adhesion dependence of GFPERK phosphorylation by probing
with antibodies to pERK and ERK. (D) HEK293 cells were cotrans-
fected with GFPERK and Raf-1 wt or estradiol-inducible Raf-1:ER.
Suspended and adherent cells were treated with or without 10 ng/ml
EGF for 5 min or 100 nM -estradiol for 10 min as indicated and
analyzed for adhesion dependence of GFPERK phosphorylation by
Western blotting with antibodies to pERK and ERK.
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pended cells, more extensive phosphorylation of S338 by PAK
165 is required.
Raf-1 S338D partially rescues signaling to ERK in sus-
pended cells. PAK165 may phosphorylate many proteins
within a cell, including MEK1 (27), which is directly down-
stream of Raf-1 in this pathway. PAK phosphorylation of
MEK1 is required for adhesion-induced rather than growth
factor-dependent ERK activation (49). However, we wanted to
more definitively determine the role of S338 in adhesion-de-
pendent signaling through the use of a phospho-mimetic Raf-1
mutant, S338D. We quantitated HA-ERK activation in NIH
3T3 cells coexpressing vector, Raf-1 wt, Raf-1 S338D, or Raf-1
S338A. As seen in Fig. 3A, Raf-1 S338D but not wt Raf-1
caused partial rescue of ERK activation in suspended cells. By
contrast, Raf-1 338A ablated signaling in both adherent and
suspended cells, reinforcing the observations of others (10, 13)
that S338 is critical for Raf-1 activation. The Raf-1 S338D-
mediated rescue in suspension cells was nearly identical in
strength to that seen with PAK165 (Fig. 3B). Furthermore, it
appears that PAK165 works primarily through Raf-1 S338
phosphorylation, as PAK165 and Raf-1 S338D showed no co-
operation to further enhance ERK activation in suspended
cells. Rescue of ERK activation appears to be at the level of
Raf-1, as Raf-1 S338D shows a parallel partial activation in
suspension after EGF treatment (Fig. 3C). HEK293 cells be-
have similarly to NIH 3T3 fibroblasts in terms of adhesion-
dependent ERK activation. Thus, expression of PAK165 or
Raf-1 S338D also partially rescued ERK activation in suspen-
sion in HEK293 cells (Fig. 3D).
In summary, Raf-1 S338 phosphorylation is not activating by
itself, but is a required step for EGF-mediated Raf-1 and
subsequent ERK activation that is lost when cells are placed in
suspension. In adhered cells a modest level of S338-phosphor-
ylated Raf-1 is sufficient to permit full activation of ERK; this
is not significantly enhanced by increasing 338 phosphorylation
by PAK165 or by use of the phospho-mimetic 338D mutant
(Fig. 2B and 3B). This suggests that the relatively small pool of
phosphorylated Raf-1 is efficiently utilized and activated in
attached cells. In contrast, restoration of Raf-1 S338 phosphor-
ylation by PAK165 (or use of the phospho-mimetic mutant
Raf-1 S338D) allows for partial rescue of ERK activation in
suspended cells. However, a larger fraction of the Raf-1 pool
needs to be phosphorylated, suggesting that other adhesion-
dependent functions influence the efficient activation of Raf-1.
Raf phosphorylation at S338 is critical for membrane-local-
ized Raf. We wished to explore the relative contributions of
membrane localization and S338 phosphorylation in Raf-1 ac-
tivation and downstream signal transduction. We found that
Raf-1 S338 phosphorylation is important even for membrane-
localized Raf-1. Flag-tagged versions of Raf-1, Raf-1CAAX,
and Raf-1CAAX S338A were transfected into HEK293 cells
and assayed for adhesion and EGF dependence of ERK acti-
vation (Fig. 3E). Flag–Raf-1 wt-expressing cells showed nor-
mal adhesion and EGF dependence of ERK activation.
Activation of ERK in Raf-1CAAX-expressing cells was inde-
pendent of both adhesion and EGF, while expression of Raf-
1CAAX S338A inhibited ERK activation. Interestingly, Raf-
1CAAX maintained elevated S338 phosphorylation in
suspension. These results are similar to published observations
that showed that both membrane localization (to specific mem-
brane compartments) and S338 phosphorylation are important
for Raf-1 activation (8). Thus, Raf-1 S338 phosphorylation is
induced upon membrane localization but is also a separate step
required for Raf-1 activation.
Inhibition of PKA in suspended cells rescues ERK signaling
through a Raf-1 S338-dependent mechanism. Activation of
PKA has long been known to inhibit growth factor activation of
ERK in fibroblasts (7, 22). PKA is transiently activated upon
detachment or changes in cell shape (34). PKA activation leads
FIG. 2. Raf-1 S338 phosphorylation is a critical adhesion-depen-
dent step in ERK activation. (A) Cell adhesion affects ERK and Raf
338 phosphorylation. Suspended and adherent NIH 3T3 fibroblasts
were treated with EGF. Whole-cell lysates were probed for pERK and
ERK, and Raf-1 immunoprecipitates were probed for Raf-1 and pS338
Raf-1. (B) Effect of activated PAK on Raf 338 phosphorylation. NIH
3T3 fibroblasts expressing Flag–Raf-1 and vector or constitutively ac-
tive PAK1 (PAK165) were starved and treated as in panel A. Flag
immunoprecipitates were probed with Raf-1 and pS338 antibodies.
(C) Effect of activated PAK on ERK kinase activity. NIH 3T3 fibro-
blasts expressing HA-ERK and vector or PAK165 were assayed for
adhesion-dependent HA-ERK activation. A representative blot of im-
munoprecipitated HA-ERK and an autoradiograph for 32P incorpora-
tion into MBP are shown. Bars represent means and standard errors of
three experiments.
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FIG. 3. Raf-1 S338 phosphorylation and phospho-mimetic 338D substitution yield partial rescue of Raf and ERK activation in suspension.
(A) Effect of Raf-1 mutants on signaling in suspension. Adhesion dependence of HA-ERK activation by EGF was quantified in NIH 3T3 cells
coexpressing vector, Flag–Raf-1 wt, Flag–Raf-1 338A, or Flag–Raf-1 338D. Cells were serum starved and maintained in suspension (Fn) or
adhered (Fn) for 2 h before 5-min EGF treatment (10 ng/ml) (means and standard errors of at least three experiments). (B) Effects of PAK 165
on signaling in suspension. Adhesion dependence of HA-ERK activation by EGF was quantified in NIH 3T3 cells coexpressing Flag–Raf-1 wt or
Flag–Raf-1 338D, with or without PAK165. (C) Raf activity in suspension. Adhesion dependence of Flag–Raf-1 wt and Flag-Raf-1 338D activation
by EGF was quantified in NIH 3T3 cells. Raf activation was determined by Raf-coupled kinase reaction of Flag immunoprecipitates. (D) Effects
of PAK165 and Raf mutants in HEK293 cells. HEK293 cells expressing GFPERK were cotransfected with Flag–Raf-1 wt, Flag–Raf-1 wt and
PAK165, or Flag–Raf-1 338D. Whole-cell lysates were probed with pERK and ERK antibodies. (E) Relative roles of membrane localization and
S338 phosphorylation in Raf signaling. HEK293 cells were transfected with GFPERK and Flag–Raf-1 wt, Flag–Raf-1CAAX, or Flag–Raf-1CAAX
338A. Cells were serum starved, and adhesion dependence of GFPERK activation was assessed as previously described. Whole-cell lysates were
probed for pERK, ERK, Flag, and pS338 Raf. Note: As indicated with asterisks, Flag-Raf CAAX contains tandem Flag tags and therefore runs
slightly higher on a gel and is detected more readily than the singly tagged Flag–Raf-1 wt.
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to alterations in the cytoskeleton, loss of tyrosine phosphory-
lation on crucial structural proteins such as FAK and paxillin,
and loss of PAK activation (34), as well as direct phosphory-
lation and inhibition of Raf-1 (26). As shown previously, ex-
pression of a PKA inhibitor peptide (PKI) permits activation
of ERK by EGF in suspension cells (34).
PKA could inhibit Raf-1 either through PAK inhibition or
through direct inhibitory phosphorylation of Raf-1. In the lat-
ter case, blockade of PKA’s direct effects on Raf-1 might sup-
plement the only partial rescue of ERK activation in sus-
pended cells by PAK165 or Raf-1 S338D. Alternatively, if PKA
acted through PAK, then the effects of inhibition of PKA
should parallel those caused by activation of PAK. Figure 4A
shows that treatment of NIH 3T3 fibroblasts with the PKA
inhibitor H-89 led to partial rescue of EGF-mediated S338
phosphorylation of endogenous Raf-1 as well as a partial res-
cue of ERK activation in suspended cells. Similarly, cells ex-
pressing PKI, an inhibitor of PKA, also showed partial rescue
of signaling to ERK in suspension (Fig. 4B); as well, PKI
expression partially rescued S338 phosphorylation in suspen-
sion (data not shown). Importantly, cells coexpressing both
PKI and Raf-1 338D showed no cooperation or enhancement
in terms of rescue of ERK activation in suspension (Fig. 4B).
Finally, PKI failed to rescue ERK activation in Raf-1 S338A-
expressing cells (Fig. 4C). These data suggest that PKA inhi-
bition rescues ERK activation in suspended cells primarily
through a mechanism that involves Raf-1 S338 phosphoryla-
tion.
PKA blocks ERK activation through inhibition of Raf-1
S338 phosphorylation. PKA is activated in cells upon a rise in
cyclic AMP, which can be produced by treatment with the
phosphodiesterase inhibitor IBMX and/or the adenylyl cyclase
agonist forskolin, as well as by cell detachment. In adherent
NIH 3T3 fibroblasts, IBMX treatment alone caused a moder-
ate increase in phosphorylation of the PKA target CREB but
had little effect on EGF-dependent Raf-1 S338 phosphoryla-
tion or ERK activation. Forskolin-IBMX treatment inhibited
ERK activation by EGF at 2 M forskolin and to a greater
degree at 50 M forskolin (Fig. 5A); this correlated well with
CREB phosphorylation. Examination of Raf-1 phosphoryla-
tion showed that S338 phosphorylation was sensitive to Fsk-
IBMX treatment and closely correlated with ERK activation.
In addition, Raf-1 S259 phosphorylation was elevated in ad-
herent cells treated with increasing forskolin-IBMX concen-
trations. In contrast, in suspended cells, despite transient acti-
vation of PKA (as judged by CREB phosphorylation), Raf-1
S259 phosphorylation was not increased but rather diminished
over time in suspension. The reason for this is unclear but may
relate to the activation of phosphatases in nonadherent cells
(38). In addition, the amount of 14-3-3 protein associated with
Raf-1 remains intact in suspended cells despite the low phos-
phorylation of S259 and S43 (see Fig. S1 in the supplemental
material). Thus, loss of ERK activity in suspended cells seems
more closely correlated with loss of the permissive S338 phos-
phorylation rather than increased inhibitory phosphorylation
at S259.
Raf-1 phosphorylated on S338 can activate ERK despite
high S259 phosphorylation. Figure 5B shows further evidence
that PKA inhibits ERK activation primarily by affecting Raf-1
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FIG. 4. Inhibition of PKA leads to partial rescue of ERK activation
and Raf-1 S338 phosphorylation in suspension. (A) Effect of the PKA
inhibitor H89. NIH 3T3 fibroblasts were pretreated for 1 h with DMSO
() or H89 (10 M) and maintained in suspension (Fn) or adhered
(Fn) for 2 h before a 5-min treatment with 10 ng/ml EGF. Whole-cell
lysates were probed for pERK and ERK; endogenous Raf immuno-
precipitates were blotted for Raf and pS338. (B) Effect of PKI on ERK
activity. Adhesion dependence of HA-ERK activation by EGF was
quantified in NIH 3T3 cells coexpressing either Flag–Raf-1 wt or
Flag–Raf-1 338D with a plasmid encoding the PKA inhibitor peptide
PKI () or a control, double point mutation of PKI mut2 () peptide
(means and standard errors of three experiments). (C) Lack of effect
of PKI on Raf 338A. Similar adhesion dependence of HA-ERK acti-
vation by EGF was quantified in NIH 3T3 cells coexpressing either
Flag–Raf-1 wt or Flag–Raf-1 338A with a plasmid encoding the PKA
inhibitor peptide PKI () or the PKI mut2 () peptide.
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was able to sustain ERK activation even at high levels of PKA
activation. NIH 3T3 cells transfected with GFPERK showed
diminished activation loop phosphorylation at or above 2 M
forskolin. However, cells coexpressing GFPERK and PAK165
showed strong ERK activation by EGF up to 10 M forskolin.
HEK293 cells showed a similar signaling profile with regard
to adhesion and PKA activation (Fig. 5C). Cells transfected
with GFPERK and Flag–Raf-1 wt and treated with EGF
showed dramatic inhibition of GFPERK phosphorylation at
both 10 and 50 M forskolin. However, PAK165-expressing
cells showed little inhibition at 10 M and only moderate
inhibition at 50 M forskolin. In adherent control cells, PKA
inhibition of ERK seems to work though PAK, as ERK acti-
vation parallels pS338 status. With PAK165 expression and
increased S338 phosphorylation, ERK activation diminished
only at high forskolin levels. This suggests that low-level PKA
activity inhibits the ERK pathway primarily by blocking S338
phosphorylation of Raf-1, while at high levels of PKA activity
additional inhibitory mechanisms come into play.
Phosphorylation was readily detected at Raf-1 S43 and S259
sites at high doses of forskolin-IBMX. However, ERK activa-
tion was strong in cells with high levels of phosphorylation at
S43 and S259, provided that S338 also was highly phosphory-
lated.
In a similar fashion, placing NIH 3T3 fibroblasts in suspen-
sion led to diminished phosphorylation of Raf-1 on S43, S259,
and S338 sites in control cells and all but S338 in PAK165-
containing cells (data not shown). Once again, these observa-
tions suggest that cell adhesion affects Raf-1 primarily by re-
ducing S338 phosphorylation rather than by increasing
phosphorylation of negative regulatory sites such as S259.
Raf-1 is required for EGF-dependent ERK activation
events. We wanted to determine the relative contributions of
Raf-1 and B-Raf in EGF-dependent ERK activation in the
cells studied here. A number of papers have suggested a role
for B-Raf in Raf-1 activation (43). Active Ras can induce
heterodimerization of B-Raf and Raf-1 (54), and certain B-Raf
mutations have been shown to activate ERK through transac-
tivation of Raf-1 (53). In addition, some suggest that B-Raf is
the main isoform that couples Ras to MEK (55). This appears
to be clearly the case for certain cell types and extracts, par-
ticularly from the brain (9, 35). However, in other circum-
stances Raf-1 seems to make a strong contribution to ERK
activation (14, 56). Determination of the role of endogenous
B-Raf is difficult, as it has higher activity but lower expression
in many tissues (31). Kidney tissue, from which HEK293 cells
are derived, has been shown to have low levels of B-Raf
mRNA (5). In addition, B-Raf is activated more robustly by
serum and Raf-1 is more robustly activated by polypeptide
growth factors, while both respond well to phorbol esters (46).
The relative roles of Raf-1 and B-Raf were pursued using
RNA interference. As seen in Fig. 6A, in cells treated with a
control siRNA that did not affect Raf-1 levels, EGF clearly
stimulated Raf-1 S338 phosphorylation as well as GFPERK
activation; this was blocked by treatment with forskolin, and
the forskolin effect was reversed by coexpression of PAK165,
similar to the results described above. In contrast, in cells
treated with Raf-1 siRNA the levels of Raf-1 protein were
sharply reduced and little activation of GFPERK was detected,
even in cells cotransfected with PAK165. This suggests an
FIG. 5. Loss of ERK activation parallels Raf-1 S338 phosphoryla-
tion in cells treated with forskolin and IBMX. (A) Effects of forskolin
or cell suspension on phosphorylation of ERK, Raf-1, and CREB.
Adherent NIH 3T3 fibroblasts were pretreated for 30 min with 100 M
IBMX and 0, 2, 10, or 50 M forskolin and compared to cells placed
in suspension for 15, 45, or 120 min. Cells were treated with 10 ng/ml
EGF for 5 min as indicated. Whole-cell lysates were probed for ERK
phosphorylation, and PKA activation was assessed with phospho-spe-
cific CREB antibodies. Raf-1 immunoprecipitates were assessed for
pS338, pS259, and Raf-1. (B) Active PAK antagonizes the inhibitory
effect of forskolin on ERK. NIH 3T3 fibroblasts expressing GFPERK,
PAK165, and PKI as indicated were pretreated with 100 M IBMX
and 2, 10, or 50 M forskolin for 30 min before EGF treatment.
Whole-cell lysates were probed for pERK and ERK. (C) Effects of
forskolin, active PAK, and cell suspension on phosphorylation of ERK
and Raf-1. HEK293 cells were cotransfected with GFPERK, Flag–
Raf-1 wt, and PAK165 as indicated. Adherent cells were pretreated for
30 min with DMSO (first two lanes) or 100 M IBMX and 2, 10, or 50
M forskolin. Adherent cells were compared to cells placed in sus-
pension for 15 min or 2 h. Whole-cell lysates were probed for pERK
and ERK. Flag (Raf-1) immunoprecipitates were probed for pS43,
pS259, pS338, and Flag (Raf-1).
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important role for Raf-1 in the signaling events studied here.
In addition, the data imply that PAK165 appears to protect
cells against forskolin-induced inhibition of ERK activation
through a Raf-1-dependent mechanism.
In contrast, EGF-dependent ERK activation was indepen-
dent of B-Raf. We could not detect endogenous B-Raf in
HEK293 cells; further, these cells activate ERK very poorly in
response to 10% FBS, suggesting a lack of this isoform (data
not shown). A proven human B-Raf siRNA sequence (33, 36)
showed successful knock-down of B-Raf expressed from a co-
transfected plasmid (Fig. 6B). Use of this siRNA versus any
possible endogenous B-Raf resulted in only slight inhibition of
EGF-stimulated GFPERK activation. Thus, the siRNA exper-
iments suggest that Raf-1, rather than B-Raf, is the key inter-
mediary in signaling to ERK in the system studied here. Thus,
perturbations of the phosphorylation status of endogenous or
transfected Raf-1 will impact on the downstream signaling to
ERK.
DISCUSSION
A major goal of our research was to determine if PAK
activation and/or Raf-1 S338 phosphorylation is a key adhe-
sion-dependent regulatory step for efficient activation of ERK.
Our results do indeed indicate that adhesion-dependent regu-
lation of ERK activation is primarily at the level of S338 phos-
phorylation of Raf-1. However, restoration of Raf-1 or ERK
activation in suspended cells by PAK165 or Raf-1 338D ex-
pression is only partial, indicating other levels of anchorage
regulation. Although Raf regulation seems to be key, this does
not exclude additional loci of anchorage regulation at the level
or MEK (27, 49) or even ERK itself (38).
Our data also suggest that, in the adherent state, the signal-
ing that leads to Raf-1 and ERK activation involves a relatively
small fraction of the population of Raf-1. Raf-1 S338 phos-
phorylation following EGF treatment is quite low compared to
that seen in cells expressing PAK165, though Raf-1and ERK
activation are similar or even more robust. This agrees with
reports that show that only a small amount of Raf-1 translo-
cates to the membrane and binds Ras (32).
One interesting set of findings refers to the roles of PAK and
PKA in Raf-1 activation in relation to adhesion. As we re-
ported previously (34) and confirm here, signaling in the ERK
pathway in suspended cells can be rescued, at least in part, by
either expression of an activated PAK or by inhibition of PKA
activity. Here we add an important observation that, despite
PKA activation upon cell detachment, Raf-1 is largely dephos-
phorylated on the potential inhibitory PKA sites of S43 and
S259, as well as on the permissive S338 site. Thus, rather than
excessive phosphorylation of Raf inhibitory sites, it is the PKA-
related loss of Raf-1 S338 phosphorylation that appears most
critical in reducing signaling in suspended cells. In this way we
see the role of PKA activation as being indirect. The low-level
transient activation of PKA caused by detachment could con-
tribute to reduced PAK activity through several mechanisms.
PKA activation can directly phosphorylate and inhibit PAK,
contribute to cytoskeletal disruption (34, 52), or even possibly
act through disruption of lipid rafts seen in nonadherent cells
(18); however, it is unlikely that adhesion-related PKA activa-
tion blocks signaling by direct phosphorylation of inhibitory
sites on Raf-1. Although PAK165 clearly phosphorylates S338,
we cannot discount the possibility of kinases other than PAK
being involved in the phosphorylation of this site (11, 39).
However, our observations suggest that other S338 kinases
would also be inhibited by PKA.
A second important observation is that cells that maintain
high Raf-1 S338 phosphorylation are refractory to PKA activity
and high S43 and S259 phosphorylation. This appears contra-
dictory to the notion that strong phosphorylation of these sites
leads to an inhibited conformation of Raf-1. Notably, Dhillon
et al. described the importance of S259 phosphorylation in
forskolin-dependent inhibition of Raf-1 (24). A critical obser-
vation is that Raf-1 S259A-expressing cells are resistant to
PKA-dependent inhibition of Raf activation. However, there
may be experimental differences that contribute to the discor-
dant results. These studies (24) used Cos cells, in which fors-
kolin does not inhibit S338 phosphorylation stimulated by
TPA. We find these cells also do not display adhesion-depen-
dent regulation of ERK activation by EGF (unpublished ob-
FIG. 6. Raf-1 is essential for ERK activation by EGF and for
PAK165-dependent rescue of ERK activation in cells treated with
forskolin and IBMX. (A) Effects of Raf-1 siRNA. HEK293 cells were
transfected with GFPERK, vector (), or PAK165 () and with 50
nM control siRNA (MDR1) or Raf-1 siRNA. After 36 h, cells were
serum starved for 12 h, pretreated with DMSO (FSK) or forskolin
(10 M) and IBMX (50 M) (FSK ) for 1 h. Wells were dosed with
10 ng/ml EGF for 5 min. Whole-cell lysates were probed for pERK,
ERK, Raf, and p338 Raf. (B) Effects of B-Raf siRNA. HEK293 cells
were transfected with GFPERK, vector (), or B-Raf (), and 50 nM
siRNAs to control (MDR1), B-Raf, or Raf-1 and recovered for 36 h.
Cells were serum starved for 12 h and dosed with 10 ng/ml EGF for 5
min. Whole-cell lysates were probed for pERK, ERK, Raf-1, and
B-Raf.
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servations). In contrast, forskolin does inhibit PAK activation
(34) and S338 phosphorylation in the NIH 3T3 and HEK293
cells used here. An observation consistent with our results is
that a Raf-1 S259A/S338A mutation abolishes both basal and
stimulated Raf-1 activation (40), implying an intrinsic role for
S338 phosphorylation (57).
We do not discount the role of Raf-1 S259 and S43 phos-
phorylation in Raf-1 inhibition under normal circumstances.
Full functional binding of Ras to Raf-1 requires two competent
binding sites (15, 21), either of which may be inhibited by
phosphorylation at S43 or S233/S259 (26). Both these sites may
contribute to a thermodynamic hurdle that Raf-1 must sur-
mount for full activation. A significant consequence of the
complete Ras–Raf-1 interaction seems to be to render Raf-1
competent for S338 phosphorylation. Our results fit well with,
and add to, models recently proposed by other laboratories
(23, 40). Using several mutations, Light et al. showed that mere
Ras–Raf-1 interaction was insufficient for Raf-1 activation
(40). While not the direct focus of their study, there was a
strong correlation between the ability of Ras mutations to
displace 14-3-3 from the Raf-1 S259 region (and induce S338
phosphorylation) and their ability to activate Raf-1. Mutation
of S259 to alanine produces Raf-1 that is unable to bind 14-3-3
at this site and is more readily phosphorylated on S338 (24),
and dephosphorylation of S259 correlates with increased S338
phosphorylation (23). Taken together, these data support the
hypothesis that phospho-S259 acts as a negative regulator of a
complete Ras–Raf-1 interaction and subsequent S338 phos-
phorylation. Our data are the first to show kinase activation
when Raf-1 is highly phosphorylated on both the positive and
negative regulatory sites. We conclude that S259 phosphoryla-
tion is not intrinsically inhibitory, but that it prevents essential
S338 phosphorylation. Thus, when strong S338 phosphoryla-
tion is provided by PAK165, pS43 and pS259 are no longer
inhibitory.
A quite different system suggests similar conclusions. When
the C-terminal catalytic domain of Raf-1 is expressed in cells,
it is highly active but is inhibited by coexpression of the N
terminus. Several labs have reported that the role of phosphor-
ylation in the region of S338 or Y341 is to relieve N-terminal
autoinhibition of Raf-1 (17, 51). However, Chong and Guan
recently proposed an alternate theory about how the N termi-
nus blocks the Raf-1 catalytic domain (12). Their data suggest
that the N terminus regulates Raf-1 by inhibiting the necessary
positive phosphorylation sites. Mutations, such as S338A, when
expressed in the truncated C-terminal catalytic domain are
inactive, which implies a positive role for S338 phosphorylation
that is intrinsic to the kinase domain and separate from relief
of autoinhibition. In addition, C-terminal truncations contain-
ing Raf-1 S338D or Y341D mutations are active, even when
the N terminus is coexpressed and despite the fact that the N
terminus remains bound to the kinase domain. Our results fit
well with their hypothesis that the negative inhibition occurs
through prevention of the required permissive (S338 or Y341)
phosphorylations.
In conclusion, we have shown that phosphorylation of Raf-1
S338 is a critical step in EGF activation of ERK that is lost in
nonadherent cells. Lack of Raf-1 activation in suspension is not
due to excessive phosphorylation of Raf-1 on negative regula-
tory sites but primarily due to reduced S338 phosphorylation
by PAK (and possibly other kinases). Thus, phosphorylation on
the negative regulatory sites S43 and S259 cannot prevent
Raf-1 activation if S338 is highly phosphorylated. However,
our rescue of ERK activation in suspension with activated
PAK or Raf-1 338D expression is only partial. Thus, there are
clearly other adhesion-regulated steps required for full activa-
tion of ERK. These might involve the altered cytoskeletal
organization found in nonadherent cells, as suggested in some
studies (2). Alternately, adhesion-dependent regulation of the
Raf-1/MEK/ERK cascade may involve scaffolding proteins
such as KSR, RKIP, MP-1, and CNK. Few, if any, of these
scaffolds have been studied in an adhesion-dependent context,
but several are regulated in their activity (16, 44) and could be
subject to adhesion-dependent influences.
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